Knowledge for Growth 2011
NXTGNT presents its molecular diagnostics pipeline at Knowledge for Growth 2011
Jan Hellemans illustrates the competitive performance of NXTGNT's PCR based targeted resequencing for molecular diagnostics.
NXTGNT presents its technology offer for the design of NGS panels for targeted resequencing.
NXTGNT acquires the Wafergen Biosystems high-throughput quantitative PCR platform
The SmartChip Complete Real-Time PCR System performs real-time PCR reactions in 100 nl across a 5184 nanowell chip. It allows to define a large variety of sample and assays configurations since the SmartChip nanowell chip is a unique open format. These configurations typically range from >1200 genes plus controls for a single sample to 3 genes plus controls for several hundred samples.
TECHGENE meeting, "Next-generation sequencing in sensory disorders" workshop, Leuven, 2011
NXTGNT presents its molecular diagnostics pipeline for deafness: Daisy Flamez presents "NXTGNT test for inherited deafness": a PCR based targeted resequencing test for NGS molecular diagnostics.
NXTGNT publishes its Variant Identification Pipeline
NXTGNT publishes "Analysing 454 amplicon resequencing experiments using the modular and database oriented Variant Identification Pipeline" in BMC Bioinformatics. Full text is available online
NXTGNT acquires Covaris DNA shearing instrument
The Covaris S2 extends the range of applications and streamlines NXTGNT's sequencing workflow.
Genetic test for heriditary deafness is available
Monogenic hearing loss (HL) is an extremely heterogeneous trait, with over 100 mapped loci and 46 causally implicated genes. Autosomal recessive non-syndromal HL (ARNSHL) occurs in 80% of the genetic cases and is typically prelingual.
The NXTGNT test for hereditary deafness is based on next generation sequencing analysis of more than 650 amplicons, covering the coding region and splice junctions of 15 genes.
More information on www.nxtgnt.com.
NXTGNT presents at Roche Belgium's Molecular Biology Days
Dr Jan Hellemans explains how massively parallel sequencing enables next generation molecular diagnostics. Work flow strategies, required coverage and cost reduction are discussed.